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In the present article, using human monocyte-derived macrophages
and cell lines containing integrated copies of the HIV-1 promoter, we
show the effects of TLR3 ligands on the pro-inﬂammatory cytokine IL-6.
We further show the effects of TLR3 ligands on HIV-1 transactivation
and transcription factors involved in HIV-1 replication. This article
complements the data reported by the authors, “Toll-Like receptor-3
mediates HIV-1 transactivation via NFκB and JNK pathways, and his-
tone acetylation, but prolonged activation suppresses Tat and HIV-1
replication” (Bhargavan et al., 2015) [1], and the interpretation of these
data can be found in the research article published by the authors in
Cellular Signaling in 2015 (Bhargavan et al., 2015) [1].
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
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acquiredCell culture, Real-time PCR, Luciferase assay, CAT-ELISAata format Analyzed
xperimental
factorsHuman monocyte-derived macrophages and cell lines containing integrated
copies of the HIV-1 promoter; HIV-1 infection; treatment with TLR3 ligands,
and pharmacological inhibitorsxperimental
featuresReal-time PCR, luciferase assay, and chloramphenicol acetyltransferase assayata source location University of Nebraska Medical Center, Omaha, USA
ata accessibility Data are with this articleDValue of the data The approach used in this data article allows for the prediction of biological pathways involved in
receptor–ligand interactions.
 Data on the mechanistic basis of TLR3-HIV interactions would be useful to others investigating viral
transactivation and replication.
 Others interested in studying the functional effects of receptor–ligand interactions could learn
from our approach.
 This approach would be of interest when determining the critical role of time on gene transcription
and expression.1. Data
To determine whether the TLR3 ligand polyinosinic-polycytidylic acid (PIC) can interact with HIV-1 to
affect gene transcriptional regulation in human monocyte-derived macrophages (MDM), time-dependent
and concentration-dependent real-time PCR analyses were performed on uninfected or HIV-1 infected
human MDM treated with PIC. Genes analyzed included the pro-inﬂammatory cytokine IL-6 and tran-
scription factors known to regulate the HIV-1 promoter activity (STAT-1, REL-B, JUN, CEBPA, and CEBPG). To
investigate the role and involvement of these transcription factors in TRL3-mediated HIV-1 transactivation,
pharmacological inhibitors targeting their signaling pathways were used, with and without TLR3 ligands, in
luciferase and chloramphenicol acetyltransferase (CAT) ELISA assays on TZM-bl and U38 cells, both of
which contained integrated copies of the HIV-1 promoter.
2. Experimental design, materials and methods
2.1. HIV-1 infection of MDM and real-time PCR
Human MDM were obtained from freshly elutriated human monocytes as previously described [1,2],
cultured in 6-well plates (2 million cells per well), and treated with 10 or 25 μg/ml PIC for 2–120 h, with
each experimental condition performed in triplicate. In separate experiments, MDM were infected with
HIV-1ADA at a multiplicity of infection of 0.01 as previously described [1–4], with or without PIC treatment
(10 and 25 mg/ml) for 2–120 h, with each experimental condition performed in triplicate. Following
treatment, cells were harvested, total RNA was extracted using the Trizol reagent, and real-time PCR
performed as described in the main manuscript [1]. All PCR reagents, probes and primers were from
Applied Biosystems and primers IDs were as follows: CEBPA (Hs00269972_s1), CEBPG (Hs01922818_s1),
JUN (Hs99999141_s1), STAT1 (Hs00234829_m1), RELB (Hs00232399_m1), IL-6 (Hs00985639), and GAPDH
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quantify the effects of PIC (10 and 25 μg/ml) on IL-6, STAT-1, REL-B, JUN, CEBPA, and CEBPG mRNA in
uninfected (Fig. 1) and HIV-1-infected (Fig. 2) human MDM.
2.2. Luciferase and chloramphenicol acetyltransferase (CAT) assays
TZM-bl and U38 cells were treated for 48 h with PIC (25 or 50 mg/ml), with or without the inhibitor
of NFκB transcriptional activation (481406, 20 nM), the JNK inhibitor ( 420119, 10 mM), the inhibitor ofFig. 1. Real-time PCR quantiﬁcation of JUN (A), STAT1 (B), RELB (C), IL-6 (D), CEBPA (E), and CEBPG (F) mRNA in untreated and
human macrophages treated with the TLR3 ligand PIC. For both MDM treated with 10 μg/ml and 25 μg/ml PIC, *Po0.05,
1Po0.001. pPo0.001, Po0.0001, compared to untreated MDM.
Fig. 2. Real-time PCR quantiﬁcation of JUN (A), STAT1 (B), RELB (C), IL-6 (D), CEBPA (E), and CEBPG (F) mRNA in HIV-1-infected
human macrophages, untreated or treated with the TLR3 ligand PIC. *Po0.05,1Po0.001. pPo0.001, Po0.0001. P-values of
infected MDM (HIV-1) are in comparison to non-infected controls (MDM), and P-values of infected MDM treated with PIC (HIV-
1þPIC(10 μg/ml), and HIV-1þPIC(25 μg/ml)) are in comparison to infected MDM.
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condition was performed in triplicate and following treatment, cells were harvested, washed with
phosphate-buffered saline, and lysed as described [1]. Cell lysates were then used to quantify the
luciferase activity (Fig. 3A) and the CAT activity (Fig. 3B) in each sample using the Luciferase Assay
Fig. 3. Quantiﬁcation of HIV-1 transactivation in TZM-bl (A) and U38 (B) cells treated with TLR3 ligands, with or without the
inhibitor of NFκB transcriptional activation ( 481406), the JNK inhibitor ( 420119), the inhibitor of c-Jun/JNK complex ( 420130),
and the MEKK7/MKK7 inhibitor (5ZO). ***Po0.001; P-values for inhibitors-treated samples are in comparison to the HIV-1
promoter activity in PIC-treated cells.
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described in the main manuscript [1].
In separate experiments, cells were treated for 48 h with PIC (25 mg/ml), with or without the AP-1
inhibitor (SR11302, 2 mM and 10 mM), the JNK inhibitor V (420129, 10 mM and 20 mM), and the IRAK-1/
4 inhibitor (5 mM and 10 mM). Each experimental condition was performed in triplicate and following
treatment, the effects of PIC and inhibitors on HIV-1 transactivation was quantiﬁed in TZM-bl cells
(Fig. 4A) or U38 cells (Fig. 4B). The main manuscript [1] includes the manufacturer's names, catalog
numbers, and mechanisms of action of each inhibitor.
Fig. 4. Quantiﬁcation of HIV-1 transactivation in TZM-bl (A) and U38 (B) cells treated with TLR3 ligands, with or without the
inhibitor of AP-1 transcriptional activity (SR11302), the ATP-competitive inhibitor of JNK (420129), and the IRAK1/4 inhibitor
***Po0.001; P-values for inhibitors-treated samples are in comparison to the HIV-1 promoter activity in PIC-treated cells.
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